Departments of Otolaryngology-Head and Neck Surgery and Plastic Surgery, University of Michigan Health System, Ann Arbor, Michigan.
Head Neck. 2013 Dec;35(12):1732-7. doi: 10.1002/hed.23216. Epub 2013 Jan 17.
The use of mandibular distraction osteogenesis (MDO) for tissue replacement after oncologic resection or for defects caused by osteoradionecrosis has been described but, in fact, has seen limited clinical utility. Previous laboratory work has shown that radiation (XRT) causes decreased union formation, decreased cellularity, and decreased mineral density in an animal model of MDO. Our global hypothesis is that radiation-induced bone damage is partly driven by the pathologic depletion of both the number and function of osteogenic cells. Parathyroid hormone (PTH) is a U.S. Food and Drug Administration-approved anabolic hormonal therapy that has demonstrated efficacy for increasing bone mineral density for the treatment of osteoporosis. We postulate that intermittent systemic administration of PTH will serve as an anabolic stimulant to cellular function that will act to reverse radiation-induced damage and enhance bone regeneration in a murine mandibular model of DO.
A total of 20 isogenic male Lewis rats were randomly assigned into 3 groups. Group 1 (XRT-DO, n = 7) and group 2 (XRT-DO-PTH, n = 5) received a human bioequivalent dose of 70 Gy fractionated over 5 days. All groups including group 3 (DO, n = 8) underwent a left unilateral mandibular osteotomy with bilateral external fixator placement. Four days later, mandibular DO was performed at a rate of 0.3 mm every 12 hours to reach a maximum gap of 5.1 mm. Group 2 was injected PTH (60 μg/kg) subcutaneously daily for 3 weeks following the start of MDO. On postoperative day 41, all left hemimandibles were harvested. Micro-CT at 45-μm voxel size was performed and radiomorphometrics parameters of bone mineralization were generated. Union quality was evaluated on a 4-point qualitative grading scale. Radiomorphometric data were analyzed using 1-way ANOVA, and union quality assessment was analyzed via the Mann-Whitney test. Statistical significance was considered at p ≤ .05.
Groups 1 and 2 appropriately demonstrated clinical signs of radiation-induced stress ranging from alopecia to mucositis. Union quality was significantly higher in PTH-treated XRT-DO animals, compared with XRT-DO group animals (p = .02). Mineralization metrics, including bone volume fraction (BVF) and bone mineral density (BMD), also showed statistically significant improvement. The groups that were treated with PTH showed no statistical differences in union or radiomorphometrics when compared with DO in nonradiated animals.
We have successfully demonstrated the therapeutic efficacy of PTH to stimulate and enhance bone regeneration in our irradiated murine mandibular model of DO. Our investigation effectively resulted in statistically significant increases in BMD, BVF, and clinical unions in PTH-treated mandibles. PTH demonstrates immense potential to treat clinical pathologies where remediation of bone regeneration is essential.
下颌骨牵引成骨术(MDO)用于肿瘤切除后的组织替代或因放射性骨坏死引起的缺损已经被描述过,但实际上,其临床应用非常有限。以前的实验室工作表明,在 MDO 的动物模型中,辐射(XRT)会导致骨愈合减少、细胞减少和矿物质密度降低。我们的总体假设是,辐射引起的骨损伤部分是由成骨细胞数量和功能的病理性减少所驱动的。甲状旁腺激素(PTH)是一种获得美国食品和药物管理局批准的合成代谢激素治疗药物,已被证明可有效增加骨质疏松症的骨矿物质密度。我们推测,间歇性全身给予 PTH 将作为一种对细胞功能的合成代谢刺激物,作用是逆转辐射引起的损伤,并增强在接受 MDO 的鼠类下颌模型中的骨再生。
总共 20 只同基因雄性 Lewis 大鼠被随机分为 3 组。第 1 组(XRT-DO,n = 7)和第 2 组(XRT-DO-PTH,n = 5)接受了 70 Gy 的人生物等效剂量,分为 5 天。所有组,包括第 3 组(DO,n = 8),均接受了左侧单侧下颌骨切开术和双侧外固定器放置。4 天后,以 0.3mm 的速度进行 MDO,每 12 小时一次,达到最大间隙 5.1mm。第 2 组在 MDO 开始后每天皮下注射 PTH(60μg/kg)3 周。术后第 41 天,收获所有左侧半下颌骨。以 45-μm 体素大小进行 micro-CT,生成骨矿化的放射形态计量学参数。使用 4 分定性分级量表评估联合质量。通过单因素方差分析分析放射形态计量数据,通过曼-惠特尼检验分析联合质量评估。p≤0.05 被认为具有统计学意义。
第 1 组和第 2 组均适当表现出从脱发到粘膜炎的辐射应激的临床迹象。与 XRT-DO 组动物相比,接受 PTH 治疗的 XRT-DO 动物的联合质量显著更高(p = 0.02)。矿化指标,包括骨体积分数(BVF)和骨矿物质密度(BMD),也显示出统计学上的显著改善。与未接受辐射的动物相比,接受 PTH 治疗的动物在联合或放射形态计量学方面与 DO 无统计学差异。
我们已经成功地证明了 PTH 治疗在我们的辐射诱导的鼠类下颌骨 MDO 模型中刺激和增强骨再生的疗效。我们的研究有效地导致 PTH 治疗的下颌骨中 BMD、BVF 和临床联合的统计学显著增加。PTH 具有巨大的潜力来治疗需要修复骨再生的临床病理。